R.I. Hospital study investigates if drug can slow, improve Alzheimer’s symptoms

RHODE ISLAND HOSPITAL researchers are investigating whether Troriluzole can slow and reverse cognitive decline in Alzheimer's disease patients.
PROVIDENCE – Rhode Island Hospital researchers are seeking subjects for a Phase 2 study into whether an investigational drug, Troriluzole, a new version of an ALS-slowing drug, can slow and reverse cognitive decline in Alzheimer’s patients, particularly those with moderate dementia. The Phase 2 study, called T2 Protect AD, evaluates whether Troriluzole can protect against,…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -